Keiji Inoue
Impact in
- Pulmonary and Respiratory Medicine top 0.5%
- Photodynamic Therapy Research Studies
- Renal cell carcinoma treatment
- Cancer Research top 2%
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Photodynamic Therapy Research Studies 47
- Renal cell carcinoma treatment 25
- Prostate Cancer Treatment and Research 8
- Surgery 70
- Bladder and Urothelial Cancer Treatments 33
- Co-authors
- Colin P. Dinney (19 shared papers)Taro Shuin (74 shared papers)Joel W. Slaton (17 shared papers)Paul Perrotte (8 shared papers)Robert Radinsky (5 shared papers)Takashi Karashima (66 shared papers)Beryl Y. Eve (7 shared papers)Mutsuo Furihata (33 shared papers)
- Journals
- Photodiagnosis and Photodynamic Therapy (19 papers)International Journal of Urology (18 papers)The Journal of Urology (9 papers)Surgery Today (7 papers)PLoS ONE (6 papers)
- Partner nations
- JapanUnited StatesCzechia
In The Last Decade
Keiji Inoue
238 papers receiving 5.8k citations
Peers
Comparison fields: 5 of 122
- Pulmonary and Respiratory Medicine 1.8k
- Cancer Research 822
- Oncology 1.4k
- Surgery 1.2k
- Molecular Biology 1.7k
Countries citing papers authored by Keiji Inoue
This map shows the geographic impact of Keiji Inoue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keiji Inoue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keiji Inoue more than expected).
Fields of papers citing papers by Keiji Inoue
This network shows the impact of papers produced by Keiji Inoue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keiji Inoue. The network helps show where Keiji Inoue may publish in the future.
Co-authors
The 25 scholars most cited alongside Keiji Inoue, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 249 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. | 1999 | 487 |
| 2 | Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. | 2000 | 308 |
| 3 | Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. | 1999 | 265 |
| 4 | Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. | 2000 | 194 |
| 5 | Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. | 2000 | 185 |
| 6 | 2001 | 160 | |
| 7 | The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. | 2000 | 135 |
| 8 | 2017 | 115 | |
| 9 | 2012 | 113 | |
| 10 | 2011 | 111 | |
| 11 | 2009 | 111 | |
| 12 | Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. | 1999 | 95 |
| 13 | Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. | 2000 | 94 |
| 14 | 2013 | 85 | |
| 15 | High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder. | 1993 | 81 |
| 16 | 2018 | 78 | |
| 17 | 2015 | 69 | |
| 18 | 2017 | 68 | |
| 19 | 2004 | 67 | |
| 20 | The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. | 2002 | 64 |
About Keiji Inoue
Keiji Inoue is a scholar working on Pulmonary and Respiratory Medicine, Surgery, Molecular Biology, Oncology and Cancer Research, having authored 249 papers that have together received 6.0k indexed citations. Recurring topics across this work include Photodynamic Therapy Research Studies (47 papers), Bladder and Urothelial Cancer Treatments (33 papers), Renal cell carcinoma treatment (25 papers), Cancer, Hypoxia, and Metabolism (20 papers), Angiogenesis and VEGF in Cancer (13 papers), Renal and related cancers (13 papers), Nanoplatforms for cancer theranostics (12 papers) and Prostate Cancer Treatment and Research (8 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.8k citations), Cancer Research (822 citations), Oncology (1.4k citations), Surgery (1.2k citations) and Molecular Biology (1.7k citations). Keiji Inoue has collaborated with scholars based in Japan, United States and Czechia. Frequent co-authors include Colin P. Dinney, Taro Shuin, Joel W. Slaton, Paul Perrotte, Robert Radinsky, Takashi Karashima, Beryl Y. Eve, Mutsuo Furihata, Daniel J. Hicklin and Hideo Fukuhara. Their work appears in journals such as Photodiagnosis and Photodynamic Therapy, International Journal of Urology, The Journal of Urology, Surgery Today and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.